Personensuche

Personensuche

Bitte geben Sie den Namen der gesuchten Person ein.

Es wurde 1 Person gefunden.

Prof. Dr. med. Max Ernst Scheulen

E-Mail
max.scheulen@uni-essen.de

Funktionen

  • , Innere Klinik (Tumorforschung)

Aktuelle Veranstaltungen

Keine aktuellen Veranstaltungen.

Vergangene Veranstaltungen (max. 10)

Keine vergangenen Veranstaltungen.

Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.

    Artikel in Zeitschriften

  • Wildner, Dane; Heinzerling, Lucie; Scheulen, Max E.; Kaempgen, Eckhart; Schuler, Gerold; Strobel, Deike; Janka, Rolf; Neurath, Markus F.; Sturm, Joerg; Knieling, Ferdinand
    Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US)
    In: Journal of Cancer Research and Clinical Oncology, Jg. 148, 2022, S. 955 – 965
    DOI (Open Access)
  • Welt, Anja; Bogner, Simon; Arendt, Marina; Kossow, Josef; Huffziger, Antonia; Pohlkamp, Christian; Steiniger, Heike; Becker, Ute; Alashkar, Ferras; Kohl, Marzena; Wiesweg, Marcel; Richly, Heike; Hense, Jörg; Scheulen, Max Ernst; Schuler, Martin; Seeber, Siegfried; Tewes, Mitra
    Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer center
    In: Journal of Cancer Research and Clinical Oncology, 2020
    DOI (Open Access)
  • Scheulen, Max Ernst; Kaempgen, Eckhart; Keilholz, Ulrich; Heinzerling, Lucie; Ochsenreither, Sebastian; Abendroth, Annalena; Huger, Ralf A.; Grubert, Matthias; Wetter, Axel; Guberina, Nika; Bauer, Sebastian; Schuler, Gerold; Bornfeld, Norbert; Schuler, Martin; Richly, Heike
    STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)
    2017 ASCO Annual Meeting, June 2-6, 2017, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. 15, 9511
    DOI
  • Mross, Klaus; Richly, Heike; Frost, Annette; Scharr, Dirk; Nokay, Bahar; Graeser, Ralph; Lee, Chooi; Hilbert, James; Goeldner, Rainer-George; Fietz, Oliver; Scheulen, Max Ernst
    A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    In: Cancer Chemotherapy and Pharmacology, Jg. 78, 2016, Nr. 2, S. 405 – 417
    DOI (Open Access)
  • Bitzer, Michael; Horger, Marius; Giannini, Edoardo G; Ganten, Tom M; Wörns, Marcus A; Siveke, Jens T.; Dollinger, Matthias M; Gerken, Guido; Scheulen, Max Ernst; Wege, Henning; Zagonel, Vittorina; Cillo, Umberto; Trevisani, Franco; Santoro, Armando; Montesarchio, Vincenzo; Malek, Nisar P; Holzapfel, Julia; Herz, Thomas; Ammendola, Astrid S; Pegoraro, Stefano; Hauns, Bernhard; Mais, Anna; Lauer, Ulrich M; Henning, Stefan W; Hentsch, Bernd
    Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study
    In: Journal of Hepatology, Jg. 65, 2016, Nr. 2, S. 280 – 288
    DOI
  • Bergmann, Lothar; Maute, Luise; Heil, G.; Rüssel, Jörn; Weidmann, Eckhart; Köberle, Dieter; Fuxius, Stefan; Weigang-Köhler, Karin; Aulitzky, Walter E.; Wörmann, B.; Hartung, G.; Moritz, B.; Edler, Lutz A.; Burkholder, Iris; Scheulen, Max Ernst; Richly, Heike
    A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
    In: European Journal of Cancer (EJC), Jg. 51, 2015, Nr. 1, S. 27 – 36
    DOI
  • Bodoky, György; Scheulen, Max Ernst; Rivera, Fernando; Jassem, Jacek; Carrato, Alfredo; Moiseyenko, Vladimir; Vynnychenko, Ihor; Prausová, Jana; Van Laethem, Jean-Luc; Cascinu, Stefano; Ajani, Jaffer A.
    Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus cisplatin/5-FU : secondary end point results from the first-line advanced gastric cancer study (FLAGS)
    In: Journal of Gastrointestinal Cancer, Jg. 46, 2015, Nr. 2, S. 109 – 117
    DOI
  • Mross, Klaus B.; Scharr, Dirk; Richly, Heike; Bauer, Sebastian; Krauss, Babett; Krauss, Rolf; Hauns, Bernhard; Prenzel, Tanja; Kohlhof, Hella; Baumgartner, Roland; Scheulen, Max Ernst
    Overcoming the proliferation rate paradox : Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205
    In: Journal of Clinical Oncology (JCO), Jg. 33, 2015, Nr. 15_suppl, S. 2528
    DOI, Online Volltext
  • Weihrauch, Martin R.; Richly, Heike; Bergwelt-Baildon, Michael S. von; Becker, Hans J.; Schmidt, Manuel; Hacker, Ulrich T.; Shimabukuro-Vornhagen, Alexander; Holtick, Udo; Nokay, Bahar; Schroff, Matthias; Wittig, Burghardt; Scheulen, Max Ernst
    Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
    In: European Journal of Cancer (EJC), Jg. 51, 2015, Nr. 2, S. 146 – 156
    DOI
  • Van den Berg, P. J.; Ruppert, M.; Sykora, K. W.; Beier, R.; Beelen, Dietrich; Hilger, Ralf A.; Scheulen, Max Ernst; Wachowiak, J.; Nemecek, E. R.; Spaans, E.; Lioznov, M.; Pichlmeier, U.; Wullf, B.; Baumgart, J.
    A preliminary population pharmacokinetic model for doese selection of treosulfan used in conditioning treatment prior to haematopoietic stem cell transplantation (HSCT) in children
    In: Bone Marrow Transplantation, Jg. 49, 2014, Nr. Suppl. 1, S. S360 – S361
    DOI
  • Infante, Jeffrey R.; Somer, Bradley G.; Park, Joon Oh; Li, Chung-Pin; Scheulen, Max Ernst; Kasubhai, Saifuddin M.; Oh, Do-Youn; Liu, Yuan; Redhu, Suman; Steplewski, Klaudia; Le, Ngocdiep
    A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
    In: European Journal of Cancer (EJC), Jg. 50, 2014, Nr. 12, S. 2072 – 2081
    DOI
  • Mross, Klaus; Scheulen, Max Ernst; Strumberg, Dirk; Kuhlmann, Jan; Kanefendt, Friederike; Sörgel, Fritz; Jaehde, Ulrich; Burkholder, Iris; Moritz, Berta; Büchert, Martin
    FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 52, 2014, Nr. 8, S. 642 – 652
    DOI
  • Leyvraz, S.; Piperno-Neumann, S.; Suciu, S.; Baurain, J. F.; Zdzienicki, M.; Testori, A.; Marshall, E.; Scheulen, Max Ernst; Jouary, T.; Negrier, S.; Vermorken, J. B.; Kaempgen, E.; Durando, X.; Schadendorf, Dirk; Gurunath, R. K.; Keilholz, U.
    Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trial
    In: Annals of Oncology, Jg. 25, 2014, Nr. 3, S. 742 – 746
    DOI
  • Bauer, Sebastian; Hilger, Ralf A.; Mühlenberg, Thomas; Grabellus, Florian; Nagarajah, James; Hoiczyk, M.; Reichardt, A.; Ahrens, M.; Reichardt, P.; Grunewald, S.; Scheulen, Max Ernst; Pustowka, A.; Bock, E.; Schuler, Martin; Pink, D.
    Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    In: British Journal of Cancer (BJC), Jg. 110, 2014, Nr. 5, S. 1155 – 1162
    DOI (Open Access)
  • Plummer, Ruth; Madi, Ayman; Jeffels, Melinda; Richly, Heike; Nokay, Bahar; Rubin, Stephen; Ball, Howard A.; Weller, Steve; Botbyl, Jeffrey; Gibson, Diana M.; Scheulen, Max Ernst
    A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    In: Cancer Chemotherapy and Pharmacology, Jg. 71, 2013, Nr. 1, S. 93 – 101
    DOI
  • Mayer, Erica L.; Scheulen, Max Ernst; Beckman, J.; Richly, Heike; Duarte, A.; Cotreau, M.M.; Strahs, A.L.; Agarwal, S.; Steelman, L.; Winer, E.P.; Dickler, M.N.
    A Phase i dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    In: Breast Cancer Research and Treatment, Jg. 140, 2013, Nr. 2, S. 331 – 339
    DOI
  • Maison-Blanche, Pierre; Vermorken, Jan B.; Goksel, Tuncay; Machiels, Jean-Pascal; Agarwala, Sanjiv; Rottey, Sylvie; Daugaard, Gedske; Volovat, Constantin; Scheulen, Max Ernst; Sengeløv, Lisa; Grecea, Dana; Eniu, Alexandru; Jäger, Elke; Meiri, Eyal; Cascinu, Stefano; Strumberg, Dirk; Demir, Gokhan; Clemens, Michael; Pinotti, Graziella; Nardi, Mario; Guthrie, Troy; Boelle, Emmanuelle; Magherini, Emmanuelle
    A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
    In: Journal of Cardiovascular Pharmacology, Jg. 61, 2013, Nr. 6, S. 495 – 504
    DOI
  • Infante, Jeffrey R.; Somer, Bradley G.; Park, Joon Oh; Li, Chung-Pin; Scheulen, Max Ernst; Kasubhai, Saifuddin M.; Oh, Do-Youn; Liu, Yuan; Lahiri, Soumi; Steplewski, Klaudia; Le, Ngocdiep T.
    A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, S. 291 – 291
    DOI
  • Slingerland, Marije; Guchelaar, Henk-Jan; Rosing, Hilde; Scheulen, Max Ernst; van Warmerdam, Laurence J.C.; Beijnen, Jos H.; Gelderblom, Hans
    Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil : A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer
    In: Clinical Therapeutics, Jg. 35, 2013, Nr. 12, S. 1946 – 1954
    DOI
  • Westekemper, Henrike; Freistühler, Michael; Bornfeld, Norbert; Steuhl, Klaus-Peter; Scheulen, Max Ernst; Hilger, Ralf A.
    Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents
    In: Graefes Archive for Clinical and Experimental Ophthalmology, Jg. 251, 2013, Nr. 1, S. 279 – 284
    DOI
  • Mross, Klaus; Richly, Heike; Fischer, Richard; Scharr, Dirk; Büchert, Martin; Stern, Angelika; Gille, Hendrik; Audoly, Laurent P.; Scheulen, Max Ernst
    First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors
    In: PLoS ONE, Jg. 8, 2013, Nr. 12, S. e83232
    DOI (Open Access)
  • Welt, Anja; Tewes, Mitra; Aktas, Bahriye; Hoffmann, Oliver; Wiesweg, Marcel; Ting, Saskia; Reis, Henning; Worm, Karl; Richly, Heike; Hense, Jörg; Palmer, Michael R.; Lee, Benjamin H.; Wendling, Johanna; Kossow, Josef; Scheulen, Max Ernst; Lehnerdt, Cathrin; Kohl, Marzena; Derks, Cordula; Skottky, Silke; Haus, Ulrike; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin; Kasper, Stefan
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients
    In: Breast Cancer Research and Treatment, Jg. 142, 2013, Nr. 1, S. 81 – 88
    DOI
  • Richly, Heike; Maute, L.; Heil, G.; Russel, J.; Jager, E.; Koeberle, D.; Fuxius, S.; Weigang-Koehler, K.; Aulitzky, W.; Woehrmann, B.; Hartung, G. G.; Moritz, B.; Burkholder, I.; Scheulen, Max Ernst; Bergmann, L.
    Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : A study of the CESAR Central European Society for Anticancer Drug Research-EWIV
    In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 15 Suppl., S. 4035
    DOI
  • Metz, C. H.; Scheulen, Max Ernst; Bornfeld, Norbert; Lohmann, Dietmar; Zeschnigk, Michael
    Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma
    In: Cancer Medicine, Jg. 2, 2013, Nr. 2, S. 208 – 215
    DOI
  • Mross, Klaus; Dittrich, Christian H.; Aulitzky, Walter Erich; Strumberg, Dirk; Schütte, Jochen J.; Schmid, Roland Michael; Hollerbach, Stephan H.; Merger, Michael; Munzert, Gert; Fleischer, Frank; Scheulen, Max Ernst
    A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-nave patients with unresectable exocrine adenocarcinoma of the pancreas-a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
    In: British Journal of Cancer (BJC), Jg. 107, 2012, Nr. 2, S. 280 – 286
    DOI (Open Access)
  • Lutscher, N.; Hones, S.; Grubert, M.; Scheulen, Max Ernst; Hilger, Ralf A.
    Antitumoral Activity of a New Class of Triazenes
    In: European Journal of Cancer (EJC), Jg. 48, 2012, Nr. Suppl. 6, S. 27 – 28
  • Westekemper, Henrike; Freistühler, Michael; Anastassiou, Gerasimos; Nareyeck, Gordon; Bornfeld, Norbert; Steuhl, Klaus-Peter; Scheulen, Max Ernst; Hilger, Ralf A.
    Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations
    In: British Journal of Ophthalmology (BJO), Jg. 96, 2012, Nr. 4, S. 591 – 596
    DOI
  • Scheulen, Max Ernst; Saito, Kaku; Hilger, Ralf A.; Mende, Bastian; Zergebel, Christopher; Strumberg, Dirk
    Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
    In: Cancer Chemotherapy and Pharmacology, Jg. 69, 2012, Nr. 3, S. 753 – 761
    DOI
  • Leijen, Suzanne; Middleton, Mark R.; Tresca, Patricia; Kraeber-Bodéré, Françoise; Dieras, Veronique; Scheulen, Max Ernst; Gupta, Avinash; Lopez-Valverde, Vanesa; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J. L.; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Schellens, Jan H. M.; Eberhardt, Wilfried
    Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
    In: Clinical Cancer Research, Jg. 18, 2012, Nr. 17, S. 4794 – 4805
    DOI (Open Access)
  • Bauer, Sebastian; Hilger, Ralf A.; Grabellus, Florian; Nagarajah, James; Hoiczyk, M.; Reichardt, A.; Ahrens, M.; Pink, D.; Mühlenberg, Thomas; Scheulen, Max Ernst; Schuler, Martin; Reichardt, P.
    Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. 10032
  • Strumberg, Dirk; Schultheis, Beate; Scheulen, Max Ernst; Hilger, Ralf A.; Krauss, J.; Marschner, N.; Lordick, F.; Bach, F.; Reuter, D.; Edler, L.; Mross, K.
    Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    In: Investigational New Drugs: The Journal of New Anticancer Agents, Jg. 30, 2012, Nr. 3, S. 1138 – 1143
    DOI
  • Leyvraz, S.; Suciu, S.; Piperno-Neumann, S.; Baurain, J. F.; Zdzienicki, M.; Testori, A.; Marshall, E.; Scheulen, Max Ernst; Jouary, T.; Negrier, S.; Vermorken, J. B.; Kaempgen, E.; Durando, X.; Schadendorf, Dirk; Gurunath, R. K.; Polders, L.; De Schaetzen, G.; Vanderschaeghe, S.; Gauthier, M. P.; Keilholz, U.
    Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma : Final results of the EORTC 18021 study
    In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. 8532
  • Strumberg, Dirk; Scheulen, Max Ernst; Schultheis, B.; Richly, Heike; Frost, A.; Büchert, M.; Christensen, O.; Jeffers, M.; Heinig, R.; Boix, O.; Mross, K.
    Regorafenib (BAY 73-4506) in advanced colorectal cancer : a phase I study
    In: British Journal of Cancer (BJC), Jg. 106, 2012, Nr. 11, S. 1722 – 1727
    DOI (Open Access)
  • Raoul, Jean-Luc; Bruix, Jordi; Greten, Tim F.; Sherman, Morris; Mazzaferro, Vincenzo; Hilgard, Philip Alexander; Scherubl, Hans; Scheulen, Max Ernst; Germanidis, Georgios; Dominguez, Sophie; Ricci, Sergio; Nadel, Andrea; Moscovici, Marius; Voliotis, Dimitris; Llovet, Josep M.
    Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function : SHARP trial subanalyses
    In: Journal of Hepatology, Jg. 56, 2012, Nr. 5, S. 1080 – 1088
    DOI
  • Schultheis, Beate; Strumberg, Dirk; Bergmann, Lothar; Graeven, Ullrich; Hanauske, Axel-Rainer; Lipp, Rainer; Schütte, Jochen; Saito, K.; Scigalla, Paul; Scheulen, Max Ernst
    Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)
    In: Investigational New Drugs: The Journal of New Anticancer Agents, Jg. 30, 2012, Nr. 3, S. 1184 – 1192
    DOI
  • Hilger, Ralf A.; Wegener, T.; Richly, Heike; Lutscher, N.; Ludwig, G.; Mross, K.; Scheulen, Max Ernst
    A clinical phase I study evaluating tolerability and pharmacokinetics (PK) of TriN 2755 in patients (pts) with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)
    In: Onkologie, Jg. 34, 2011, Nr. Suppl. 6, S. 109 – 110
  • Saif, M. W.; Lichinitser, M.; Gordon, M. S.; Tan, B. R.; Scheulen, Max Ernst; Pandya, N. B.; Sarantopoulos, J.; Rinehart, J. J.; Verschraegen, C. F.; Lenz, H.; Zergebel, C.; Saito, K.
    A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function
    In: Journal of Clinical Oncology (JCO), Jg. 29, 2011, Nr. 15_suppl, S. e13089
    DOI
  • Mross, K.; Büchert, M.; Fasol, U.; Jaehde, U.; Kanefendt, F.; Strumberg, Dirk; Arends, J.; Hense, Jörg; Moritz, B.; Fischer, R.; Scheulen, Max Ernst
    A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 49, 2011, Nr. 1, S. 96 – 98
    DOI
  • Kanefendt, F.; Lindauer, A.; Kinzig, M.; Strumberg, Dirk; Scheulen, Max Ernst; Mross, K.; Fischer, R.; Moritz, B.; Sörgel, Fritz; Jaehde, U.
    Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 49, 2011, Nr. 1, S. 88 – 90
  • Westekemper, Henrike; Freistühler, Michael; Anastassiou, Gerasimos; Nareyeck, G.; Zeschnigk, Michael; Bornfeld, Norbert; Steuhl, Klaus-Peter; Scheulen, Max Ernst; Hilger, Ralf A.
    Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 49, 2011, Nr. 1, S. 78 – 80
  • Mayer, E. L.; Scheulen, Max Ernst; Beckman, J.; Richly, Heike; Poli, A.; Bhargava, P.; Duarte, A.; Cotreau, M. M.; Strahs, A. L.; Dickler, M. N.
    Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer : Results of a phase I study
    In: Journal of Clinical Oncology (JCO), Jg. 29, 2011, Nr. 15_suppl, S. 1092
    DOI
  • Leijen, S.; Middleton, M. R.; Tresca, P.; Kraeber-Bodere, F.; Dieras, V.; Scheulen, Max Ernst; Tessier, J.; Xu, Z. X.; Shochat, E.; Walz, A.; Deutsch, J.; Blotner, S.; Lopez Valverde, V.; Naegelen, V. M.; Schellens, J. H. M.; Eberhardt, Wilfried
    Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor
    In: Journal of Clinical Oncology (JCO), Jg. 29, 2011, Nr. 15_suppl, S. 3017
    DOI
  • Mross, K.; Frost, A.; Scheulen, Max Ernst; Krauss, J.; Strumberg, Dirk; Schultheiss, B.; Fasol, U.; Buchert, M.; Kratzschmer, J.; Delesen, H.; Rajagopalan, P.; Christensen, O.
    Phase I study of telatinib (BAY 57-9352) : analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
    In: Vascular Cell, Jg. 3, 2011, S. 16
    DOI
  • Holtick, Udo; Scheulen, Max Ernst; Von Bergwelt-Baildon, Michael S; Weihrauch, Martin R
    Toll-like receptor 9 agonists as cancer therapeutics
    In: Expert Opinion on Investigational Drugs, Jg. 20, 2011, Nr. 3, S. 361 – 372
    DOI
  • Heusner, Till Alexander; Antoch, G.; Wittkowski-Sterczewski, A.; Ladd, Susanne; Forsting, Michael; Verhagen, R.; Scheulen, Max Ernst
    Transarterial hepatic chemoperfusion of uveal melanoma metastases : Survival and response to treatment
    In: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Jg. 183, 2011, Nr. 12, S. 1151 – 1160
    DOI
  • Edler, L.; Sehrt, D.; Scheulen, Max Ernst
    10 Years CESAR Anticancer Drug Research : The 7th CESAR Annual Meeting 2009. Preface
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 48, 2010, Nr. 7, S. 435 – 439
    DOI
  • Schmidt, M.; Holtick, U.; Nokay, B.; Richly, Heike; Tschaika, M.; Wittig, B.; von Bergwelt-Baildon, M.S.; Scheulen, Max Ernst; Weihrauch, M.R.; Hacker, U.
    46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study
    In: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 23 – 24
    DOI (Open Access)
  • Nokay, B.; Richly, Heike; Hacker, U.; Wittig, B.; Weihrauch, M.R.; Schmidt, M.; Shimabukuro-Vornhagen, A.; Scheulen, Max Ernst; von Bergwelt-Baildon, M.S.; Tschaika, M.
    47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study
    In: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 24
    DOI (Open Access)
  • Lee, K.H.; Hilbert, Josef; Mross, K.; Fietz, O.; Scharr, D.; Scheulen, Max Ernst; Richly, Heike; Nokay, B.; Frost, A.; Saunders, O.
    496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours
    In: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 158 – 159
    DOI (Open Access)
  • Rubin, S.D.; Plummer, R.; Scheulen, Max Ernst; Nokay, B.; Madi, A.; Richly, Heike; Jeffels, M.; Gibson, D.; Weller, S.
    50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors
    In: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 25
    DOI (Open Access)
  • Scheulen, Max Ernst; Mross, K. B.; Richly, Heike; Nokay, B.; Frost, A.; Scharr, D.; Lee, K.; Saunders, O.; Hilbert, Josef; Fietz, O.
    A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors
    In: Journal of Clinical Oncology (JCO), Jg. 28, 2010, Nr. Suppl. 15, S. e13065
    DOI
  • Al-Adhami, M.; Beckman, J.; Dickler, M.; Scheulen, Max Ernst; Mayer, E. L.; Poli, A.; Bhargava, P.; Duarte, A.; Richly, Heike; Cotreau, M.
    Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer : Preliminary Results of an Ongoing Phase 1 Study
    In: Cancer Research, Jg. 70, 2010, Nr. 24, S. P2 – 16
    DOI
  • Schmidt, Martina; Scheulen, Max Ernst; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Rüttinger, D.; Schuler, Martin; Reinhardt, C.; Awada, A.
    An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    In: Annals of Oncology, Jg. 21, 2010, Nr. 2, S. 275 – 282
    DOI
  • Westekemper, Henrike; Akgül, Harun; Scharifi, M.; Anastassiou, Gerasimos; Nareyeck, G.; Freistühler, Michael; Zeschnigk, Michael; Lohmann, Dietmar; Bornfeld, Norbert; Steuhl, Klaus-Peter; Scheulen, Max Ernst; Hilger, Ralf A.
    Chemosensitivity of conjunctival melanoma cell lines
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,
    In: Onkologie, Jg. 33, 2010, Nr. Suppl. 6, S. 66
    DOI
  • Strumberg, Dirk; Bergmann, Lothar; Graeven, U.; Hanauske, A.; Lipp, R.; Schuette, J.; Schultheis, B.; Scigalla, P.; Urrea, P.; Scheulen, Max Ernst
    First-line treatment of patients with metastatic pancreatic cancer : Results of a Phase II trial with S-1 (CESAR-Study group)
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 48, 2010, Nr. 7, S. 470 – 472
    DOI
  • Strumberg, Dirk; Schultheis, B.; Scheulen, Max Ernst; Hilger, Ralf A.; Krauss, J.; Marschner, N.; Lordick, F.; Bach, F.; Reuter, D.; Edler, L.; Mross, K.
    Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    In: International Journal of Clinical Pharmacology and Therapeutics, Jg. 48, 2010, Nr. 7, S. 473 – 475
    DOI
  • Koeppen, Susanne; Verstappen, C.C.P.; Körte, R.; Scheulen, Max Ernst; Strumberg, Dirk; Postma, T.J.; Heimans, J.J.; Huijgens, P.C.; Kiburg, B.; Renzing-Köhler, K.; Diener, Hans Christoph; K�rte, R.; Renzing-K�hler, K.
    Lack of neuroprotection by an ACTH (4-9) analogue : A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma
    In: Journal of Cancer Research and Clinical Oncology, Jg. 130, 2004, Nr. 3, S. 153 – 160
    DOI
  • Bojko, P.; Hilger, Ralf A.; Ruehm, S.G.; Dirsch, O.; Seeber, S.; Scheulen, Max Ernst
    Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation
    In: Bone Marrow Transplantation, Jg. 31, 2003, Nr. 6, S. 487 – 491
    DOI (Open Access)

    • Abstracts

  • Mross, K. B.; Scharr, D.; Richly, Heike; Frost, A.; Bauer, Sebastian; Krause, B.; Krause, R.; Mals, A.; Hauns, B.; Hentsch, B.; Baumgartner, R.; Scheulen, Max Ernst
    First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein
    2014 ASCO Annual Meeting, 30 May to 3 June 2014, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15, Suppl., 2564
    DOI
  • Welt, Anja; Kasper, Stefan; Tewes, Mitra; Aktas, B.; Hoffmann, Oliver; Wiesweg, M.; Ting, Saskia; Reis, Henning; Worm, K.; Richly, Heike; Hense, Jörg; Palmer, M. R.; Lee, B. H.; Wendling, J.; Kossow, J.; Scheulen, Max Ernst; Lehnerdt, C.; Kohl, M.; Derks, C.; Slottky, S.; Haus, U.; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19
    DOI (Open Access)
  • Richly, Heike; Scheulen, Max Ernst; Wiesweg, Marcel; Abendroth, A.; Schuler, Martin; Bauer, Sebastian
    Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
    31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin, Germany,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 37, 2014, Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 – 119
    DOI
  • Tewes, Mitra; Kasper, Stefan; Aktas, B.; Hoffmann, A.; Wiesweg, M.; Ting, Saskia; Reis, Henning; Worm, K.; Richly, Heike; Hense, Jörg; Kern, P.; Scheulen, Max Ernst; Skottky, S.; Peters, M.; Schlegel, R.; Lee, B. H.; Palmer, M. R.; Monahan, J. E.; Haus, U.; Schmid, Kurt Werner; Kimmig, Rainer; Schuler, Martin; Welt, Anja
    Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
    Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 157
    DOI
  • Bitzer, M.; Ganten, T. M.; Woerns, M. A.; Siveke, Jens T.; Dollinger, M. M.; Scheulen, Max Ernst; Wege, H.; Giannini, E. G.; Cillo, U.; Trevisani, F.; Santoro, A.; Montesarchio, V.; Mais, A.; Hauns, B.; Asche, J.; Herz, T.; Pegoraro, S.; Ammendola, A.; Henning, S. W.; Hentsch, B.; SHELTER Study Grp
    Resminostat in advanced hepatocellular carcinoma (HCC) : Overall survival subgroup analysis of prognostic factors in the SHELTER trial
    2013 ASCO Annual Meeting, 30 May - 3 Jun 2013, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 31, 2013, Nr. 15 Suppl., e15088
    DOI
  • Scheulen, Max Ernst; Richly, Heike; Kalkavan, H.; Hoffmann, Andreas-Claudius; Virchow, I.; Hilger, Ralf A.; Koeppen, Susanne; Sure, Ulrich; Schuler, Martin; Hense, Jörg
    An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
    48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 30, 2012, Nr. 15, Suppl., 2086
    DOI
  • Hilger, Ralf A.; Wegener, Tobias; Richly, Heike; Ludwig, Georg; Mross, Klaus; Scheulen, Max Ernst
    A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)
    In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 71, 2011, Nr. 8, Suppl., S. 1293
    DOI
  • Mross, K. B.; Scheulen, Max Ernst; Frost, A.; Scharr, D.; Richly, Heike; Nokay, B.; Lee, K.; Hilbert, J.; Fleischer, F.; Fietz, O.
    A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors
    In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 28, 2010, Nr. 15 Suppl., S. 3011
  • Kalkmann, J.; Richly, Heike; Forsting, Michael; Scheulen, Max Ernst; Stattaus, Jörg
    Detection of new hepatic metastases in computed tomography (CT) with hepatic metastatic choroidal melanoma in Antiangiogenic Therapy - Progress or Pseudoprogression?
    29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,
    In: Onkologie. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 2, S. 188
    DOI
  • Kalkmann, J.; Richly, Heike; Forsting, Michael; Scheulen, Max Ernst; Stattaus, Jörg
    Evaluation of lesions density in computed tomography (CT) for assessment of tumor response in patients with hepatic metastatic choroidal melanoma under therapy with sorafenib
    29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,
    In: Oncology Research and Treatment. Basel: Karger, Jg. 33, 2010, Nr. Suppl. 2, S. 182
    DOI

    • Poster / Posterbeiträge

  • Bitzer, Michael; Horger, Markus; Ganten, Tom; Ebert, Matthias P.; Siveke, Jens T.; Woerns, Marcus A.; Dollinger, Matthias M.; Gerken, Guido; Scheulen, Max Ernst; Mais, Anna; Jankowsky, Rüdiger; Hauns, Bernhard; Hentsch, Bernd; Lauer, Ulrich M.
    Clinical update on the phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC) - The Shelter Study
    13th World Congress on Gastrointestinal Cancer 22–25 June 2011, Barcelona, Spain,
    In: Annals of Oncology. Amsterdam: Elsevier, Jg. 22, 2011, Nr. Suppl. 5, S. v76 – v76
    DOI
  • Scheulen, Max Ernst; Nokay, B.; Richly, Heike; Hoffmann, Andreas-Claudius; Kalkmann, J.; Stattaus, Jörg; Bornfeld, Norbert; Schuler, Martin; Hense, Jörg
    Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)
    EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’, 27-29 October 2011, Brussels, Belgium,
    In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 47, 2011, Nr. Suppl. 4, S. S30
    DOI